Cargando…

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study

Uveal melanoma is the most common primary intraocular malignancy in adults. Up to 50% of UM patients develop metastatic disease, usually in the liver. When metastatic, the prognosis is poor, and few treatment options exist. Here, we investigated the feasibility of establishing patient-derived xenogr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nemati, Fariba, de Koning, Leanne, Gentien, David, Assayag, Franck, Henry, Emilie, Ait Rais, Khadija, Pierron, Gaelle, Mariani, Odette, Nijnikoff, Michèle, Champenois, Gabriel, Nicolas, André, Meseure, Didier, Gardrat, Sophie, Servant, Nicolas, Hupé, Philippe, Kamal, Maud, Le Tourneau, Christophe, Piperno-Neumann, Sophie, Rodrigues, Manuel, Roman-Roman, Sergio, Decaudin, Didier, Mariani, Pascale, Cassoux, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604955/
https://www.ncbi.nlm.nih.gov/pubmed/37887557
http://dx.doi.org/10.3390/curroncol30100657
_version_ 1785126958427799552
author Nemati, Fariba
de Koning, Leanne
Gentien, David
Assayag, Franck
Henry, Emilie
Ait Rais, Khadija
Pierron, Gaelle
Mariani, Odette
Nijnikoff, Michèle
Champenois, Gabriel
Nicolas, André
Meseure, Didier
Gardrat, Sophie
Servant, Nicolas
Hupé, Philippe
Kamal, Maud
Le Tourneau, Christophe
Piperno-Neumann, Sophie
Rodrigues, Manuel
Roman-Roman, Sergio
Decaudin, Didier
Mariani, Pascale
Cassoux, Nathalie
author_facet Nemati, Fariba
de Koning, Leanne
Gentien, David
Assayag, Franck
Henry, Emilie
Ait Rais, Khadija
Pierron, Gaelle
Mariani, Odette
Nijnikoff, Michèle
Champenois, Gabriel
Nicolas, André
Meseure, Didier
Gardrat, Sophie
Servant, Nicolas
Hupé, Philippe
Kamal, Maud
Le Tourneau, Christophe
Piperno-Neumann, Sophie
Rodrigues, Manuel
Roman-Roman, Sergio
Decaudin, Didier
Mariani, Pascale
Cassoux, Nathalie
author_sort Nemati, Fariba
collection PubMed
description Uveal melanoma is the most common primary intraocular malignancy in adults. Up to 50% of UM patients develop metastatic disease, usually in the liver. When metastatic, the prognosis is poor, and few treatment options exist. Here, we investigated the feasibility of establishing patient-derived xenografts (PDXs) from a patient’s tumor in order to screen for therapies that the patient could benefit from. Samples obtained from 29 primary tumors and liver metastases of uveal melanoma were grafted into SCID mice. PDX models were successfully established for 35% of primary patient tumors and 67% of liver metastases. The tumor take rate was proportional to the risk of metastases. PDXs showed the same morphology, the same GNAQ/11, BAP1, and SF3B1 mutations, and the same chromosome 3 and 8q status as the corresponding patient samples. Six PDX models were challenged with two compounds for 4 weeks. We show that, for 31% of patients with high or intermediate risk of metastasis, the timing to obtain efficacy results on PDX models derived from their primary tumors was compatible with the selection of the therapy to treat the patient after relapse. PDXs could thus be a valid tool (“avatar”) to select the best personalized therapy for one third of patients that are most at risk of relapse.
format Online
Article
Text
id pubmed-10604955
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106049552023-10-28 Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study Nemati, Fariba de Koning, Leanne Gentien, David Assayag, Franck Henry, Emilie Ait Rais, Khadija Pierron, Gaelle Mariani, Odette Nijnikoff, Michèle Champenois, Gabriel Nicolas, André Meseure, Didier Gardrat, Sophie Servant, Nicolas Hupé, Philippe Kamal, Maud Le Tourneau, Christophe Piperno-Neumann, Sophie Rodrigues, Manuel Roman-Roman, Sergio Decaudin, Didier Mariani, Pascale Cassoux, Nathalie Curr Oncol Article Uveal melanoma is the most common primary intraocular malignancy in adults. Up to 50% of UM patients develop metastatic disease, usually in the liver. When metastatic, the prognosis is poor, and few treatment options exist. Here, we investigated the feasibility of establishing patient-derived xenografts (PDXs) from a patient’s tumor in order to screen for therapies that the patient could benefit from. Samples obtained from 29 primary tumors and liver metastases of uveal melanoma were grafted into SCID mice. PDX models were successfully established for 35% of primary patient tumors and 67% of liver metastases. The tumor take rate was proportional to the risk of metastases. PDXs showed the same morphology, the same GNAQ/11, BAP1, and SF3B1 mutations, and the same chromosome 3 and 8q status as the corresponding patient samples. Six PDX models were challenged with two compounds for 4 weeks. We show that, for 31% of patients with high or intermediate risk of metastasis, the timing to obtain efficacy results on PDX models derived from their primary tumors was compatible with the selection of the therapy to treat the patient after relapse. PDXs could thus be a valid tool (“avatar”) to select the best personalized therapy for one third of patients that are most at risk of relapse. MDPI 2023-10-11 /pmc/articles/PMC10604955/ /pubmed/37887557 http://dx.doi.org/10.3390/curroncol30100657 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nemati, Fariba
de Koning, Leanne
Gentien, David
Assayag, Franck
Henry, Emilie
Ait Rais, Khadija
Pierron, Gaelle
Mariani, Odette
Nijnikoff, Michèle
Champenois, Gabriel
Nicolas, André
Meseure, Didier
Gardrat, Sophie
Servant, Nicolas
Hupé, Philippe
Kamal, Maud
Le Tourneau, Christophe
Piperno-Neumann, Sophie
Rodrigues, Manuel
Roman-Roman, Sergio
Decaudin, Didier
Mariani, Pascale
Cassoux, Nathalie
Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
title Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
title_full Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
title_fullStr Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
title_full_unstemmed Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
title_short Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
title_sort patient derived xenografts (pdx) models as an avatar to assess personalized therapy options in uveal melanoma: a feasibility study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604955/
https://www.ncbi.nlm.nih.gov/pubmed/37887557
http://dx.doi.org/10.3390/curroncol30100657
work_keys_str_mv AT nematifariba patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT dekoningleanne patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT gentiendavid patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT assayagfranck patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT henryemilie patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT aitraiskhadija patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT pierrongaelle patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT marianiodette patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT nijnikoffmichele patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT champenoisgabriel patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT nicolasandre patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT meseuredidier patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT gardratsophie patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT servantnicolas patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT hupephilippe patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT kamalmaud patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT letourneauchristophe patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT pipernoneumannsophie patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT rodriguesmanuel patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT romanromansergio patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT decaudindidier patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT marianipascale patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy
AT cassouxnathalie patientderivedxenograftspdxmodelsasanavatartoassesspersonalizedtherapyoptionsinuvealmelanomaafeasibilitystudy